Izalontamab Brengitecan in Recurrent or Metastatic Esophageal Squamous Cell Carcinoma: The PANKU-Esophagus01 Randomized Clinical Trial Key Points Question Does izalontamab brengitecan improve progression-free survival (PFS) and overall survival compared with chemotherapy in patients with recurrent or metastatic esophageal squamous cell carcinoma who progressed after first-line programmed cell death 1 protein/programmed cell death 1 ligand 1 inhibitor plus platinum-containing chemotherapy?
Buhai Wang
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile
Get in touch with Buhai
Contact Buhai, search articles and posts on X, monitor coverage, and track replies from one place.
Learn more about Muck Rack